Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

NASDAQ:ABEO - Nasdaq - US00289Y2063 - Common Stock - Currency: USD

6.45  +0.03 (+0.47%)

After market: 6.45 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ABEO. ABEO was compared to 561 industry peers in the Biotechnology industry. ABEO may be in some trouble as it scores bad on both profitability and health. ABEO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABEO had negative earnings in the past year.
ABEO had a negative operating cash flow in the past year.
In the past 5 years ABEO always reported negative net income.
In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ABEO's Return On Assets of -58.51% is in line compared to the rest of the industry. ABEO outperforms 40.11% of its industry peers.
ABEO has a worse Return On Equity (-144.75%) than 62.75% of its industry peers.
Industry RankSector Rank
ROA -58.51%
ROE -144.75%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
The number of shares outstanding for ABEO has been increased compared to 5 years ago.
Compared to 1 year ago, ABEO has a worse debt to assets ratio.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -8.56, we must say that ABEO is in the distress zone and has some risk of bankruptcy.
ABEO has a worse Altman-Z score (-8.56) than 72.19% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that ABEO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.30, ABEO is not doing good in the industry: 71.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -8.56
ROIC/WACCN/A
WACC10.1%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ABEO has a Current Ratio of 6.08. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
ABEO has a better Current ratio (6.08) than 63.99% of its industry peers.
ABEO has a Quick Ratio of 6.08. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
ABEO has a better Quick ratio (6.08) than 64.53% of its industry peers.
Industry RankSector Rank
Current Ratio 6.08
Quick Ratio 6.08
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.79% over the past year.
ABEO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)35.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ABEO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.45% on average per year.
Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 399.06% on average per year.
EPS Next Y91.7%
EPS Next 2Y45.14%
EPS Next 3Y38.16%
EPS Next 5Y22.45%
Revenue Next Year22192.2%
Revenue Next 2Y3181.56%
Revenue Next 3Y1148.98%
Revenue Next 5Y399.06%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ABEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ABEO's earnings are expected to grow with 38.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.14%
EPS Next 3Y38.16%

More info and screens

0

5. Dividend

5.1 Amount

ABEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (5/21/2025, 8:00:00 PM)

After market: 6.45 0 (0%)

6.45

+0.03 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08
Earnings (Next)08-11 2025-08-11
Inst Owners76.5%
Inst Owner Change-5.43%
Ins Owners7.23%
Ins Owner Change18.47%
Market Cap314.76M
Analysts86.67
Price Target20.11 (211.78%)
Short Float %11.97%
Short Ratio3.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.17%
Min EPS beat(2)-52.88%
Max EPS beat(2)61.23%
EPS beat(4)2
Avg EPS beat(4)9.49%
Min EPS beat(4)-121.54%
Max EPS beat(4)151.17%
EPS beat(8)4
Avg EPS beat(8)-4.49%
EPS beat(12)6
Avg EPS beat(12)18.98%
EPS beat(16)10
Avg EPS beat(16)15.83%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.7%
PT rev (3m)23.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.63%
EPS NY rev (1m)53.3%
EPS NY rev (3m)88.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)81.48%
Revenue NY rev (3m)12.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.15
P/tB 7.15
EV/EBITDA N/A
EPS(TTM)-1.74
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0
BVpS0.9
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.51%
ROE -144.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.08
Quick Ratio 6.08
Altman-Z -8.56
F-Score3
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)32.9%
Cap/Depr(5y)51.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
EPS Next Y91.7%
EPS Next 2Y45.14%
EPS Next 3Y38.16%
EPS Next 5Y22.45%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year22192.2%
Revenue Next 2Y3181.56%
Revenue Next 3Y1148.98%
Revenue Next 5Y399.06%
EBIT growth 1Y-33.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-56.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.36%
OCF growth 3YN/A
OCF growth 5YN/A